Acromegaly Clinical Trial
Official title:
Multicenter, Randomised Open Trial Comparing the Efficacy of a Medical Treatment With Sandostatin LP 30 mg Performed Before Surgery to a Prime Line transsphenoïdal Surgery in Previously Untreated Acromegalic Patients With Either a Micro or a Macro Pituitary Adenoma
The aim of the study is to evaluate the interest of a six month pre-operative treatment with a long-acting somatostatin analog (Sandostatin LP) versus surgery alone in patients with a pituitary adenoma responsible for acromegaly.
Somatotroph pituitary adenoma is the most frequent cause of acromegaly. A transsphenoidal removal of the tumor is used as the first line treatment. Somatostatin analogs are used as to whether recovery was not obtained after surgery or pituitary surgery was contraindicated. Previous studies with somatostatin analogs have shown a drop in plasma GH and IGF-1 levels and a reduction in adenoma size in 75 and 25% of patients respectively. Retrospective studies suggest that a treatment with somatostatin analogs performed before surgery may be of interest to improve anesthesic conditions and surgical outcome. The aim of present study is to prospectively evaluate the interest of a first line treatment with a long-acting somatostatin analog (Sandostatin) before performing a pituitary surgery in acromegalic patients with either a micro or a macroadenoma to improve peri-operative conditions and hopefully surgical outcome. After informed consent, untreated acromegalic patients will be included and randomly assigned to one of the following treatment procedures : either pituitary surgery or a six month treatment with long-acting Sandostatin 30 mg monthly for 6 months before performing transsphenoïdal adenoma removal. The patients will be evaluated before any treatment, on months 3 and 6 of the treatment with Sandostatin (for the patients enrolled in this arm of the study) and on months 3 and 12 after pituitary neurosurgery. Each evaluation will include clinical data, hormone testing and radiological (MRI) investigation. The main endpoint will be the rate of recovery proved by a normalisation of GH secretion and plasma IGF-1 level. Secondary endpoints will include the evaluation of clinical, radiological, biological, anesthesic, surgical and pathological parameters. A comparison between the two arms will be performed at entry into the study, at the time of surgery and then on months 3 and 12 following the transsphenoidal removal of the somatotroph adenoma. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06344650 -
Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
|
||
Active, not recruiting |
NCT02092129 -
Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.
|
N/A | |
Completed |
NCT02012127 -
Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
|
||
Active, not recruiting |
NCT01265121 -
Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
|
N/A | |
Terminated |
NCT00765323 -
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
|
Phase 3 | |
Completed |
NCT00500227 -
Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
|
||
Completed |
NCT00531908 -
Physiopathology of Sodium Retention in Acromegaly
|
N/A | |
Completed |
NCT01278342 -
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
|
Phase 4 | |
Active, not recruiting |
NCT01809808 -
A Prospective Study of Outcome After Therapy for Acromegaly
|
||
Completed |
NCT00145405 -
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
|
Phase 4 | |
Completed |
NCT00210457 -
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
|
Phase 3 | |
Recruiting |
NCT05401084 -
Diet in the Management of Acromegaly
|
N/A | |
Recruiting |
NCT00005100 -
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
|
N/A | |
Completed |
NCT00521300 -
Preoperative Octreotide Treatment of Acromegaly
|
Phase 4 | |
Completed |
NCT03548415 -
Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
|
Phase 2 | |
Not yet recruiting |
NCT04066569 -
Reproducibility and Utility of OGTT in Acromegaly
|
N/A | |
Not yet recruiting |
NCT05298891 -
Hypoproteic Diet in Acromegaly
|
N/A | |
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Active, not recruiting |
NCT03252353 -
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
|
Phase 3 |